Table 4 Incidence of adverse events, n (%)

From: Clustered repetitive transcranial magnetic stimulation for the prevention of depressive relapse/recurrence: a randomized controlled trial

 

rTMS + ADP

rTMS

ADP

Statistical values

 

(n = 82)

(n = 91)

(n = 108)

χ 2

P b

Diarrhea

5 (6.1)

6 (6.6)

8 (7.4)

0.133

0.936

Constipation

28 (34.1)

22 (24.2)

35 (32.4)

2.420

0.298

Dry mouth

43 (52.4)

28 (30.8)

66 (61.1)

18.827

<0.001

Nausea

3 (3.7)

7 (7.7)

8 (7.4)

1.464

0.481

Palpitations

11 (13.4)

10 (11.0)

9 (8.3)

1.276

0.528

Dizziness

8 (9.8)

14 (15.4)

8 (7.4)

3.398

0.183

Excessive sweating

32 (39.0)

16 (17.6)

32 (29.6)

9.854

0.007

Headache

6 (7.3)

13 (14.3)

2 (1.9)

11.046

0.004

Tremor

1 (1.2)

7 (7.7)

0

11.674

0.003

Poor coordination

0

7 (7.7)

0

14.989

<0.001

Blurred vision

21 (25.6)

23 (25.3)

15 (13.9)

5.345

0.069

Tinnitus

14 (17.1)

6 (6.6)

3 (2.8)

13.128

0.001

Urine frequency

17 (20.7)

6 (6.6)

7 (6.5)

12.278

0.002

Difficulty in sleeping

3 (3.7)

13 (14.3)

3 (2.8)

12.147

0.002

Sleeping too much

4 (4.9)

6 (6.6)

3 (2.8)

1.646

0.439

Loss of sexual desire

10 (12.2)

4 (4.4)

4 (3.7)

6.513

0.039

Trouble achieving orgasm

3 (3.7)

5 (5.5)

4 (3.7)

0.493

0.781

Anxiety

2 (2.4)

7 (7.7)

6 (5.6)

2.372

0.305

Difficulty in concentration

2 (2.4)

6 (6.6)

4 (3.7)

1.959

0.376

Tiredness

10 (12.2)

14 (15.4)

15 (13.9)

0.367

0.832

Decreased energy

4 (4.9)

8 (8.8)

7 (6.5)

1.069

0.586

  1. a rTMS repetitive transcranial magnetic stimulation, ADP antidepressants
  2. bd.f. = 2